Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule
Keiser AA, Matazel KS, Esser MK, Feifel D, Prus AJ
1E, P = 0.13
Current NHS eligibility criteria for semaglutide 2.4 mg (Wegovy) for weight management, according to NICE TA875, include: Body Mass Index (BMI) 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea) For people from certain high-risk ethnic groups (such as South Asian, Chinese, Black African, or African-Caribbean), lower BMI thresholds apply (typically reduced by 2.5 kg/m) Treatment must be prescribed within specialist weight management services only Treatment is limited to a maximum duration of 2 years Must be used as an adjunct to a reduced-calorie diet and increased physical activity Liraglutide 3 mg (Saxenda) availability varies significantly across NHS regions and is not routinely commissioned in many areas
2018;84:e02738-e2817
US$ 23.82
US$ 21.47
US$ 28.02
US$ 20.89
US$ 25.79
US$ 27.52
US$ 29.43
US$ 26.00
US$ 26.96
